Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

ALK-positive Advanced NSCLC Clinical Trial

Official title: A Single-Arm, Multicenter, Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate efficacy and safety of brigatinib in Japanese participants with anaplastic lymphoma kinase (ALK)-positive NSCLC.

Clinical Trial Description

The drug being tested in this study is called brigatinib. Brigatinib is being tested in participants with ALK-positive NSCLC in order to evaluate efficacy and safety of oral doses of brigatinib in Japanese participants with ALK-positive NSCLC. The study will enroll approximately 110 participants. Participants will be enrolled in non-randomized and opened manner: - Brigatinib 90 mg for the first 7 days, followed by Brigatinib 180 mg of Brigatinib tablets, once daily in a 28-days cycle. All participants will be asked to take tablets of brigatinib once daily with or without food throughout the study. This multi-center trial will be conducted in Japan. The overall time to participate in this study is approximately 53 months. Participants will make multiple visits to the clinic during the treatment period, and posttreatment period including a follow-up assessment after last dose of study drug. ;

Related Conditions & MeSH terms

• ALK-positive Advanced NSCLC
• Carcinoma, Non-Small-Cell Lung

• NCT number: NCT03410108
• Study type: Interventional
• Source: Takeda
• Status: Completed
• Phase: Phase 2
• Start date: January 29, 2018
• Completion date: July 28, 2021